Literature DB >> 21654720

Myeloproliferative neoplasms cause glomerulopathy.

Samar M Said1, Nelson Leung, Sanjeev Sethi, Lynn D Cornell, Mary E Fidler, Joseph P Grande, Sandra Herrmann, Ayalew Tefferi, Vivette D D'Agati, Samih H Nasr.   

Abstract

Myeloproliferative neoplasms are clonal hematopoietic stem cell disorders that can produce an undefined glomerulopathy. To better characterize the glomerular disease associated with myeloproliferative neoplasms, we evaluated features of 11 patients with myeloproliferative neoplasm-related glomerulopathy that included 8 patients with primary myelofibrosis, and 1 each with chronic myelogenous leukemia, polycythemia vera, and essential thrombocythemia. Indications for biopsy were nephrotic-range proteinuria (nephrotic syndrome in four) and chronic renal insufficiency. The mean time from diagnosis of the neoplasms to biopsy was 7.2 years. Histologically, mesangial sclerosis and hypercellularity were seen in all 11 cases, segmental sclerosis in 8, features of chronic thrombotic microangiopathy in 9, and intracapillary hematopoietic cells in 4. On follow-up, seven patients had persistent renal dysfunction and four progressed to end-stage renal disease (ESRD). Thus, glomerulopathy appears to be a late complication of myeloproliferative neoplasms, particularly primary myelofibrosis, with guarded prognosis. Greater awareness of this entity and larger studies are needed to define possible therapies.

Entities:  

Mesh:

Year:  2011        PMID: 21654720     DOI: 10.1038/ki.2011.147

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  25 in total

1.  Evidence for prevention of renal dysfunction associated with primary myelofibrosis by cytoreductive therapy.

Authors:  Yasutaka Fukuda; Marito Araki; Kouji Yamamoto; Soji Morishita; Tadaaki Inano; Kyohei Misawa; Tomonori Ochiai; Yoko Edahiro; Misa Imai; Hajime Yasuda; Akihiko Gotoh; Akimichi Ohsaka; Norio Komatsu
Journal:  Haematologica       Date:  2019-04-04       Impact factor: 9.941

2.  WITHDRAWN: Nephrotic syndrome in primary myelofibrosis with renal extramedullary hematopoiesis and glomerulopathy in the JAK inhibitor era.

Authors:  Rachele Del Sordo; Rachele Brugnano; Carla Covarelli; Gioia Fiorucci; Franca Falzetti; Giorgio Barbatelli; Emidio Nunzi; Angelo Sidoni
Journal:  Clin Nephrol       Date:  2017-07-24       Impact factor: 0.975

Review 3.  Kidney diseases associated with haematological cancers.

Authors:  Anirban Ganguli; Deirdre Sawinski; Jeffrey S Berns
Journal:  Nat Rev Nephrol       Date:  2015-06-02       Impact factor: 28.314

4.  A rare cause of acute kidney injury with chronic myelomonocytic leukemia.

Authors:  Marina Asano; Hanako Hase; Yuki Naruse; Kyogo Kawada; Iori Kojima; Joel Branch; Hiroshi Kitamura; Hideaki Shimizu
Journal:  CEN Case Rep       Date:  2021-01-06

5.  "Unusual Cause Of Tophi With Renal Thrombotic Microangiopathy".

Authors:  Kamal Kant Sahu; Arjun Datt Law; Ganesh Kumar; Varun Dhir; Shano Naseem; Ritambhra Nada; Subhash Chander Varma; Pankaj Malhotra
Journal:  Indian J Hematol Blood Transfus       Date:  2015-04-16       Impact factor: 0.900

6.  Focal segmental glomerulosclerosis in a patient with prefibrotic primary myelofibrosis.

Authors:  Gopal Krishana Bohra; Durga Shankar Meena; Nitin Bajpai; Abhishek Purohit
Journal:  BMJ Case Rep       Date:  2018-05-04

7.  Reduced renal function strongly affects survival and thrombosis in patients with myelofibrosis.

Authors:  Marko Lucijanic; Davor Galusic; Ivan Krecak; Martina Sedinic; Hrvoje Holik; Vlatka Perisa; Martina Moric Peric; Ivan Zekanovic; Tajana Stoos-Veic; Rajko Kusec
Journal:  Ann Hematol       Date:  2020-08-29       Impact factor: 3.673

8.  Renal extramedullary hematopoiesis: interstitial and glomerular pathology.

Authors:  Mariam P Alexander; Samih H Nasr; Paul J Kurtin; Edward T Casey; Loren P Herrera Hernandez; Mary E Fidler; Sanjeev Sethi; Lynn D Cornell
Journal:  Mod Pathol       Date:  2015-10-09       Impact factor: 7.842

9.  Myelofibrosis patients can develop extramedullary complications including renal amyloidosis and sclerosing hematopoietic tumor while otherwise meeting traditional measures of ruxolitinib response.

Authors:  Daria V Babushok; Ernest J Nelson; Jennifer J D Morrissette; Shivam Joshi; Matthew B Palmer; Dale Frank; Carolyn L Cambor; Elizabeth O Hexner
Journal:  Leuk Lymphoma       Date:  2018-09-19

Review 10.  Renovascular hypertension associated with JAK2 V617F positive myeloproliferative neoplasms treated with angioplasty: 2 cases and literature review.

Authors:  Eikan Mishima; Takehiro Suzuki; Yoichi Takeuchi; Kazumasa Seiji; Noriko Fukuhara; Kei Takase; Hideo Harigae; Takaaki Abe; Sadayoshi Ito
Journal:  J Clin Hypertens (Greenwich)       Date:  2018-04-14       Impact factor: 3.738

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.